Skip to main content
Log in

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics and biochemical efficacy of N-(2-memyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide (I) were evaluated in healthy male volunteers after single and multiple oral administration.

The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, SO and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.

The drug disappeared from the systemic circulation with half-lives (t1/2) of 4.7–7.1 h. The mean values of the area under the curve (AUC0–24) and Cmax increased linearly in a dose-dependent manner.

After multiple oral adniinistration of (I) (10 mg/d) for 7 days, Cnua and AUC increased slightly during administration, however, there were no significant differences between day 4 and day 7. Although there were large intersubject differences in the 24 h plasma levels after each dosing, no accumulation of (I) occurred after 7 days dosing.

Serum 5-α-dihydrotestosterone (DHT) was markedly reduced at all dose levels. The mean serum levels of DHT at 24 h post-dosing decreased to 27–42% of that before dosing. On the other hand, the serum testosterone (T) did not change significantly. After multiple administration of (I), serum DHT was significantly reduced and remained suppressed for up to 7 days after the final dosing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rasmusson G.H., Reynolds G.F., Utne T., et al. (1984): Azasteroids as inhibitors of rat prostatic Sa-reductase. J. Med. Chem., 27, 1690–1701.

    Article  CAS  PubMed  Google Scholar 

  2. Liang T., Cascieri M.A., Cheung A.H., Reynolds G.F., Rasmusson G.H. (1985): Species difference in prostatic steroids 5α-reductases of rat, dog and human. Endocrinology, 117, 571–579.

    Article  CAS  PubMed  Google Scholar 

  3. Brooks J.R., Berman C., Primka R.L., Reynolds G.F., Rasmusson G.H. (1986): 5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat. Steroids, 47, 1–19.

    Article  CAS  PubMed  Google Scholar 

  4. Brooks J.R., Baptiska E.M., Berman C., et al. (1981): Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology, 109, 830–836.

    Article  CAS  PubMed  Google Scholar 

  5. Wenderoth U.K., George F.W., Wilson J.D. (1983): The effect of a 5α-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology, 113, 569–573.

    Article  CAS  PubMed  Google Scholar 

  6. Brooks J.R., Berman C., Glitzer M.S., et al. (1982): Effect of a new Sa-reductase inhibitor on size, histologie characteristics and androgen concentrations of the canine prostate. Prostate, 3, 35–44.

    Article  CAS  PubMed  Google Scholar 

  7. Siiteri P.K., Wilsom J.D. (1970): Dihydrostestosterone in prostatic hypertrophy I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J. Clin. Invest., 49, 1737–1745.

    Article  CAS  PubMed  Google Scholar 

  8. Peters C., Scott W.W., Walsh P.C. (1986): The response of human BPH to androgen deprivation. J. Urol., 135, 196A.

    Google Scholar 

  9. Geller J., Albert J., Lopez D., Geller S., Niwayama G. (1976): Comparison of androgen metabolites in benign prostatic hypertrophy and normal prostate. J. Clin. Endocrinol. Metab., 43, 686–688.

    Article  CAS  PubMed  Google Scholar 

  10. Carlin J.R., Christofalo P., Vandenheuvel J.A. (1988): High-performance liquid chromatographic determination of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1 -ene- 17β-carbox amide, a 4-azasteroid in human plasma from a phase I study. J. Chromatogr., 427, 79–91.

    Article  CAS  PubMed  Google Scholar 

  11. Kawamura J., Okada K., Yoshida O., Kousaka T., Torizuka K. (1986): Testosterone radioimmunoassay with125I-testosterone kit. Kakuigaku, 23, 431–438.

    CAS  Google Scholar 

  12. Auletta F.J., Caldwell B.V., Hamilton G.L. (1974): Methods of hormone radioimmunoassay. Jaffe B.M., Behrman R.H. eds. New York, Academic Press, pp. 359–370.

    Google Scholar 

  13. Gibaldi M., Perrier D. (1982): In: Swarbrick J. ed, Pharmacokinetics. New York, Marcel Decker, pp. 149–152.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohtawa, M., Morikawa, H. & Shimazaki, J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. European Journal of Drug Metabolism and Pharmacokinetics 16, 15–21 (1991). https://doi.org/10.1007/BF03189869

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189869

Keywords

Navigation